Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.

Jimenez-Zepeda VH, Trudel S, Winter A, Reece DE, Chen C, Kukreti V.

Am J Hematol. 2012 Aug;87(8):822-3. doi: 10.1002/ajh.23235. Epub 2012 May 28. No abstract available.

2.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M.

Bone Marrow Transplant. 2012 Jan;47(1):146-8. doi: 10.1038/bmt.2011.18. Epub 2011 Feb 28. No abstract available.

PMID:
21358681
3.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
4.

Timing of the high-dose therapy in the area of new drugs.

Schmitt S, Bertsch U, Hose D, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:90-4.

5.

[Bortezomib-based therapy in patients with light chain deposition disease].

Minařík J, Tichý T, Pika T, Bačovský J, Adamová D, Srovnalík K, Krejčí K, Zadražil J, Sčudla V.

Vnitr Lek. 2014 Oct;60(10):821-6. Czech.

PMID:
25382003
6.
7.

Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.

Giglio G, Romito S, Carrozza F, Musacchio M, Antuzzi G, Gigli R, Magri M, Bavaro P, Di Bartolomeo P, Dell'Isola M, Accorsi P.

Int J Hematol. 2009 Jul;90(1):81-6. doi: 10.1007/s12185-009-0354-x. Epub 2009 Jun 16.

PMID:
19529980
8.

Plasma cell leukemia: concepts and management.

Liedtke M, Medeiros BC.

Expert Rev Hematol. 2010 Oct;3(5):543-9. doi: 10.1586/ehm.10.52. Review.

PMID:
21083471
9.

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.

Transplant Proc. 2009 Dec;41(10):4407-10. doi: 10.1016/j.transproceed.2009.10.005.

PMID:
20005409
10.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

11.

Bortezomib dosing in relapsed multiple myeloma.

Jagannath S.

Clin Lymphoma Myeloma. 2006 Sep;7(2):101-2. No abstract available.

PMID:
17026818
12.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143.

13.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
14.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
15.
16.

Re-transplantation after bortezomib-based therapy.

Morris C, Cook G, Streetly M, Kettle P, Drake M, Quinn M, Cavet J, Tighe J, Kazmi M, Ashcroft J, Cook M, Snowden J, Olujohungbe A, Marshall S, Conn J, Oakervee H, Popat R, Cavenagh J.

Br J Haematol. 2011 Jun;153(5):666-8. doi: 10.1111/j.1365-2141.2010.08521.x. Epub 2011 Jan 31. No abstract available.

PMID:
21275960
17.

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.

van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM.

Blood. 2006 Apr 15;107(8):3415-6. No abstract available.

18.

Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

Jimenez-Zepeda VH, Vajpeyi R, John R, Trudel S.

Int J Hematol. 2012 Jul;96(1):125-31. doi: 10.1007/s12185-012-1090-1. Epub 2012 May 10.

PMID:
22573235
19.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
20.

Supplemental Content

Support Center